They made it easy and had a good price
They made it easy and had a good price
By Debbie
Sunday, November 8, 2026 · Customer reviews of US businesses
The Fair Hearing score
Average
10,226 reviews
Select a line to read only those reviews.
Honesty, pricing, process and quality scores appear once 5 customers have rated them.
Embody is a modern tele-health platform helping people achieve sustainable weight loss through medically guided GLP-1 treatments. Our program connects patients with licensed providers who prescribe personalized weight loss plans using medications like semaglutide and tirzepatide - all delivered directly to their door.With plans starting at just $79/month with no long term commitment, Embody makes clinically proven metabolic care more accessible than ever. Patients complete a quick 2 minute online intake, receive a provider review, and if medically appropriate, begin treatment with ongoing medical support.
Embody (joinem.co) has 10,226 customer reviews on The Fair Hearing, with an average rating of 3.8 out of 5.
10,226 approved reviews, newest moderated first
They made it easy and had a good price
By Debbie
From start to finish everything was straight forward and easy. So far my experience with Embody was great.
By Debbie T.
Wonderful customer service! The agent took his time and explained everything.
By customer
Fast shipping! Answered all my questions. Just started so excited to see what happens
By Maria L.
Fueron directos y fácil manera de trabajar con su metodología.
By Alberto
I’ve tried several and this is the only one that’s saying my stomach really hurt!
By customer
Response from Embody· Jul 20, 2026
We are truly sorry to hear our product caused you discomfort. If you haven’t yet, please contact the care team and they will help you. In case of emergency please call 911
customer support
By Gregory R.
I still haven’t received my prescription and I’m having trouble locating logging in to the portal. I hope that they will be coming soon. Thank you Klea
By customer
Response from Embody· Jul 21, 2026
We understand your concern about the prescription and portal access. We are actively looking into these issues for you.